Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
出版年份 2019 全文链接
标题
Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
作者
关键词
Fibrate, Meta-analysis, Dyslipidemia, Pemafibrate, Adverse events, Lipid profile, Hepatobiliary enzyme activity
出版物
Cardiovascular Diabetology
Volume 18, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-03-21
DOI
10.1186/s12933-019-0845-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Triglyceride-mediated influence of serum angiopoietin-like protein 8 on subclinical atherosclerosis in type 2 diabetic patients: results from the GDMD study in China
- (2018) Tianpeng Zheng et al. Cardiovascular Diabetology
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
- (2018) Shizuya Yamashita et al. Journal of Clinical Lipidology
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
- (2018) Ikuro Matsuba et al. Journal of Diabetes Investigation
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity
- (2018) Mengdie Luo et al. Cardiovascular Diabetology
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. ATHEROSCLEROSIS
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- Altered Concentrations in Dyslipidemia Evidence a Role for ANGPTL8/Betatrophin in Lipid Metabolism in Humans
- (2016) Javier Gómez-Ambrosi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status
- (2016) Amirhossein Sahebkar et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy
- (2014) Michael H. Davidson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial
- (2014) R. Neil A. Black et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ^|^mdash;2012 Version
- (2013) Tamio Teramoto et al. Journal of Atherosclerosis and Thrombosis
- The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia
- (2013) Rohana Abdul Ghani et al. Journal of Clinical Lipidology
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Insulin Resistance and the Relationship of a Dyslipidemia to Coronary Heart Disease
- (2011) Sander J. Robins et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control
- (2010) Vincent J. Carey et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
- (2010) M. John Chapman et al. PHARMACOLOGY & THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More